<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39290710</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>18</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>19</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1664-3224</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Frontiers in immunology</Title><ISOAbbreviation>Front Immunol</ISOAbbreviation></Journal><ArticleTitle>Safety assessment of anti-B cell maturation antigen chimeric antigen receptor T cell therapy: a real-world study based on the FDA adverse event reporting system database.</ArticleTitle><Pagination><StartPage>1433075</StartPage><MedlinePgn>1433075</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1433075</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fimmu.2024.1433075</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">On April 18, 2024, the U.S. Food and Drug Administration officially required updating of the "boxed warning" for T cell malignancies for all chimeric antigen receptor T cell (CAR-T) therapies. Given the clinical significance of these therapies, a rigorous safety assessment is paramount. However, comprehensive real-world safety studies have been lacking for the newly marketed CAR-T products idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel), which target B cell maturation antigen, especially regarding the risk of secondary malignancies. Therefore, we aimed to thoroughly analyze the adverse events (AEs) information in the FDA Adverse Event Reporting System (FAERS) database to comprehensively understand the safety risks of ide-cel and cilta-cel.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">We extracted AE reports related to ide-cel and cilta-cel from the FAERS database (https://fis.fda.gov/extensions/FPD-QDE-FAERS/FPD-QDE-FAERS.html.) from January 1, 2019 to December 31, 2023. Disproportionality analysis and Bayesian analysis were used to identify risk signals across subgroups and specific cases (including for death and secondary malignancies). Weibull distribution analysis was employed to determine the time to AE onset.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">A total of 695 AE reports for ide-cel and 848 for cilta-cel were included in the FAERS database. This analysis identified 81 positive signals for ide-cel and 74 for cilta-cel. Notably, comparisons with the drug labels revealed "unexpected signals," including febrile bone marrow aplasia (reporting odds ratio=69.10; confidence interval 39.12-122.03) and plasma cell myeloma (12.45; 8.18-18.95) for ide-cel, and increased serum ferritin (24.98; 8.0-77.58) and large intestine perforation (18.57; 5.98-57.69) for cilta-cel. Both drugs showed a higher AE incidence among male recipients and patients aged ≥65 years, although female recipients faced a greater risk. Most AEs occurred at the early stage of administration. However, secondary malignancies were detected for both drugs, primarily occurring one-year post-administration.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">This study provides a foundation for understanding the safety profile of CAR-T cell therapy, particularly in relation to the emergence of secondary malignancies. Such insights are helpful for clinical decision-making and the safe and effective utilization of these therapeutic agents.</AbstractText><CopyrightInformation>Copyright © 2024 Liu, Lin, Zhu, Yin, Liu, Lei and Feng.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Wei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>The Department of Pharmacy Administration, School of Pharmacy, Xi'an Jiaotong University, Xi'an, Shaanxi, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Center for Drug Safety and Policy Research, Xi' an Jiaotong University, Xi' an, Shaanxi, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Shuzhi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>The Department of Pharmacy Administration, School of Pharmacy, Xi'an Jiaotong University, Xi'an, Shaanxi, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Center for Drug Safety and Policy Research, Xi' an Jiaotong University, Xi' an, Shaanxi, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Xiaoying</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>The Department of Pharmacy Administration, School of Pharmacy, Xi'an Jiaotong University, Xi'an, Shaanxi, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Center for Drug Safety and Policy Research, Xi' an Jiaotong University, Xi' an, Shaanxi, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yin</LastName><ForeName>Lin</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>The Department of Pharmacy Administration, School of Pharmacy, Xi'an Jiaotong University, Xi'an, Shaanxi, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Center for Drug Safety and Policy Research, Xi' an Jiaotong University, Xi' an, Shaanxi, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Qian</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>The Department of Pharmacy Administration, School of Pharmacy, Xi'an Jiaotong University, Xi'an, Shaanxi, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Center for Drug Safety and Policy Research, Xi' an Jiaotong University, Xi' an, Shaanxi, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lei</LastName><ForeName>Shuang</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>The Department of Pharmacy Administration, School of Pharmacy, Xi'an Jiaotong University, Xi'an, Shaanxi, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Center for Drug Safety and Policy Research, Xi' an Jiaotong University, Xi' an, Shaanxi, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feng</LastName><ForeName>Bianling</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>The Department of Pharmacy Administration, School of Pharmacy, Xi'an Jiaotong University, Xi'an, Shaanxi, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Center for Drug Safety and Policy Research, Xi' an Jiaotong University, Xi' an, Shaanxi, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Immunol</MedlineTA><NlmUniqueID>101560960</NlmUniqueID><ISSNLinking>1664-3224</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000076962">Receptors, Chimeric Antigen</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053301">B-Cell Maturation Antigen</NameOfSubstance></Chemical><Chemical><RegistryNumber>U2I8T43Y7R</RegistryNumber><NameOfSubstance UI="C000629083">axicabtagene ciloleucel</NameOfSubstance></Chemical><Chemical><RegistryNumber>8PX1X7UG4D</RegistryNumber><NameOfSubstance UI="C000715380">idecabtagene vicleucel</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011948">Receptors, Antigen, T-Cell</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001688">Biological Products</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016219" MajorTopicYN="Y">Immunotherapy, Adoptive</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014486" MajorTopicYN="Y">United States Food and Drug Administration</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000076962" MajorTopicYN="Y">Receptors, Chimeric Antigen</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016907" MajorTopicYN="Y">Adverse Drug Reaction Reporting Systems</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053301" MajorTopicYN="N">B-Cell Maturation Antigen</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011948" MajorTopicYN="N">Receptors, Antigen, T-Cell</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001688" MajorTopicYN="N">Biological Products</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">B cell maturation antigen</Keyword><Keyword MajorTopicYN="N">FDA adverse event reporting system</Keyword><Keyword MajorTopicYN="N">adverse events</Keyword><Keyword MajorTopicYN="N">chimeric antigen receptor T cell therapy</Keyword><Keyword MajorTopicYN="N">disproportionality analysis</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>18</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>18</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>18</Day><Hour>4</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39290710</ArticleId><ArticleId IdType="pmc">PMC11405296</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2024.1433075</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Killock D. CAR T cells show superiority over standard therapies for RRMM. Nat Rev Clin Oncol. (2023) 20:210. doi: 10.1038/s41571-023-00749-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41571-023-00749-y</ArticleId><ArticleId IdType="pubmed">36849555</ArticleId></ArticleIdList></Reference><Reference><Citation>Atrash S, Ali SA, Usmani SZ. Chimeric antigen receptor T-cell therapy for multiple myeloma. Clin Lymphoma Myeloma Leuk. (2021) 21:21–34. doi: 10.1016/j.clml.2020.08.027</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clml.2020.08.027</ArticleId><ArticleId IdType="pubmed">33046423</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadek NL, Costa BA, Nath K, Mailankody S. CAR T-cell therapy for multiple myeloma: A clinical practice-oriented review. Clin Pharmacol Ther. (2023) 114:1184–95. doi: 10.1002/cpt.3057</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cpt.3057</ArticleId><ArticleId IdType="pubmed">37750399</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma P, Kanapuru B, George B, Lin X, Xu Z, Bryan WW, et al. . FDA approval summary: idecabtagene vicleucel for relapsed or refractory multiple myeloma. Clin Cancer Res. (2022) 28:1759–64. doi: 10.1158/1078-0432.Ccr-21-3803</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.Ccr-21-3803</ArticleId><ArticleId IdType="pmc">PMC9064878</ArticleId><ArticleId IdType="pubmed">35046063</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin T, Usmani SZ, Berdeja JG, Agha M, Cohen AD, Hari P, et al. . Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed/refractory multiple myeloma: CARTITUDE-1 2-year follow-up. J Clin Oncol. (2023) 41:1265–74. doi: 10.1200/jco.22.00842</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/jco.22.00842</ArticleId><ArticleId IdType="pmc">PMC9937098</ArticleId><ArticleId IdType="pubmed">35658469</ArticleId></ArticleIdList></Reference><Reference><Citation>Natrajan K, Kaushal M, George B, Kanapuru B, Theoret MR. FDA approval summary: ciltacabtagene autoleucel for relapsed or refractory multiple myeloma. Clin Cancer Res. (2024) 30(14):2865–71. doi: 10.1158/1078-0432.Ccr-24-0378</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.Ccr-24-0378</ArticleId><ArticleId IdType="pmc">PMC11249607</ArticleId><ArticleId IdType="pubmed">38713595</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis J, McGann M, Shockley A, Hashmi H. Idecabtagene vicleucel versus ciltacabtagene autoleucel: a Sophie's choice for patients with relapsed refractory multiple myeloma. Expert Rev Hematol. (2022) 15:473–5. doi: 10.1080/17474086.2022.2081147</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17474086.2022.2081147</ArticleId><ArticleId IdType="pubmed">35603733</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang J, Zhou F. BCMA-targeting chimeric antigen receptor T cell therapy for relapsed and/or refractory multiple myeloma. Ann Hematol. (2024) 103:1069–83. doi: 10.1007/s00277-023-05444-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00277-023-05444-7</ArticleId><ArticleId IdType="pubmed">37704875</ArticleId></ArticleIdList></Reference><Reference><Citation>Chekol Abebe E, Yibeltal Shiferaw M, Tadele Admasu F, Asmamaw Dejenie T. Ciltacabtagene autoleucel: The second anti-BCMA CAR T-cell therapeutic armamentarium of relapsed or refractory multiple myeloma. Front Immunol. (2022) 13:991092. doi: 10.3389/fimmu.2022.991092</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.991092</ArticleId><ArticleId IdType="pmc">PMC9479060</ArticleId><ArticleId IdType="pubmed">36119032</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez-Otero P, Ailawadhi S, Arnulf B, Patel K, Cavo M, Nooka AK, et al. . Ide-cel or standard regimens in relapsed and refractory multiple myeloma. N Engl J Med. (2023) 388:1002–14. doi: 10.1056/NEJMoa2213614</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2213614</ArticleId><ArticleId IdType="pubmed">36762851</ArticleId></ArticleIdList></Reference><Reference><Citation>San-Miguel J, Dhakal B, Yong K, Spencer A, Anguille S, Mateos MV, et al. . Cilta-cel or standard care in lenalidomide-refractory multiple myeloma. N Engl J Med. (2023) 389:335–47. doi: 10.1056/NEJMoa2303379</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2303379</ArticleId><ArticleId IdType="pubmed">37272512</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang J, Zhou W, Li D, Niu T, Wang W. BCMA-targeting chimeric antigen receptor T-cell therapy for multiple myeloma. Cancer Lett. (2023) 553:215949. doi: 10.1016/j.canlet.2022.215949</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.canlet.2022.215949</ArticleId><ArticleId IdType="pubmed">36216149</ArticleId></ArticleIdList></Reference><Reference><Citation>
(FDA) USFaDA . FDA Requires Boxed Warning for T cell Malignancies Following Treatment with BCMA-Directed or CD19-Directed Autologous Chimeric Antigen Receptor (CAR) T cell Immunotherapies 2024. Available online at: https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/fda-requires-boxed-warning-t-cell-malignancies-following-treatment-bcma-directed-or-cd19-directed. (accessed [April 19, 2024])</Citation></Reference><Reference><Citation>Freyer CW, Porter DL. Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic Malignancies. J Allergy Clin Immunol. (2020) 146:940–8. doi: 10.1016/j.jaci.2020.07.025</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2020.07.025</ArticleId><ArticleId IdType="pubmed">32771558</ArticleId></ArticleIdList></Reference><Reference><Citation>Cordas dos Santos DM, Tix T, Rejeski K. Infections drive non-relapse mortality following CAR-T therapy across disease entities and CAR products - a meta-analysis of clinical trials and real-world studies. Blood. (2023) 142:1064–. doi: 10.1182/blood-2023-187516</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2023-187516</ArticleId></ArticleIdList></Reference><Reference><Citation>Lipe DN, Rajha E, Wechsler AH, Gaeta S, Palaskas NL, Alhajji Z, et al. . Cardiotoxicity associated with immune checkpoint inhibitors and CAR T-cell therapy. Am J Emerg Med. (2021) 50:51–8. doi: 10.1016/j.ajem.2021.07.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajem.2021.07.014</ArticleId><ArticleId IdType="pubmed">34274878</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh V, Master S. Incidence of Parkinsonism as a complication of anti-BCMA CAR-T cell therapy in multiple myeloma. Blood. (2023) 142:6937–. doi: 10.1182/blood-2023-188090</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2023-188090</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedman KM, Garrett TE, Evans JW, Horton HM, Latimer HJ, Seidel SL, et al. . Effective targeting of multiple B-cell maturation antigen-expressing hematological Malignances by anti-B-cell maturation antigen chimeric antigen receptor T cells. Hum Gene Ther. (2018) 29:585–601. doi: 10.1089/hum.2018.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/hum.2018.001</ArticleId><ArticleId IdType="pmc">PMC5930946</ArticleId><ArticleId IdType="pubmed">29641319</ArticleId></ArticleIdList></Reference><Reference><Citation>
U.S. Food and Drug Administration (FDA) . Available online at: https://www.fda.gov/drugs/surveillance/questions-and-answers-fdas-adverse-event-reporting-system-faers. (accessed [April 15, 2024])</Citation></Reference><Reference><Citation>Rodriguez EM, Staffa JA, Graham DJ. The role of databases in drug postmarketing surveillance. Pharmacoepidemiol Drug Saf. (2001) 10:407–10. doi: 10.1002/pds.615</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pds.615</ArticleId><ArticleId IdType="pubmed">11802586</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakaeda T, Kadoyama K, Minami K, Okuno Y. Commonality of drug-associated adverse events detected by 4 commonly used data mining algorithms. Int J Med Sci. (2014) 11:461–5. doi: 10.7150/ijms.7967</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/ijms.7967</ArticleId><ArticleId IdType="pmc">PMC3970098</ArticleId><ArticleId IdType="pubmed">24688309</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakaeda T, Tamon A, Kadoyama K, Okuno Y. Data mining of the public version of the FDA Adverse Event Reporting System. Int J Med Sci. (2013) 10:796–803. doi: 10.7150/ijms.6048</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/ijms.6048</ArticleId><ArticleId IdType="pmc">PMC3689877</ArticleId><ArticleId IdType="pubmed">23794943</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown EG. Using MedDRA: implications for risk management. Drug Saf. (2004) 27:591–602. doi: 10.2165/00002018-200427080-00010</Citation><ArticleIdList><ArticleId IdType="doi">10.2165/00002018-200427080-00010</ArticleId><ArticleId IdType="pubmed">15154830</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu Y, Bai Z, Tang Y, Liu R, Zhao B, Gong J, et al. . Fournier gangrene associated with sodium-glucose cotransporter-2 inhibitors: A pharmacovigilance study with data from the U.S. FDA adverse event reporting system. J Diabetes Res. (2020) 2020:3695101. doi: 10.1155/2020/3695101</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2020/3695101</ArticleId><ArticleId IdType="pmc">PMC7368210</ArticleId><ArticleId IdType="pubmed">32695827</ArticleId></ArticleIdList></Reference><Reference><Citation>Shu Y, He X, Liu Y, Wu P, Zhang Q. A real-world disproportionality analysis of olaparib: data mining of the public version of FDA adverse event reporting system. Clin Epidemiol. (2022) 14:789–802. doi: 10.2147/clep.S365513</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/clep.S365513</ArticleId><ArticleId IdType="pmc">PMC9250344</ArticleId><ArticleId IdType="pubmed">35789689</ArticleId></ArticleIdList></Reference><Reference><Citation>Bate A, Evans SJ. Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol Drug Saf. (2009) 18:427–36. doi: 10.1002/pds.1742</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pds.1742</ArticleId><ArticleId IdType="pubmed">19358225</ArticleId></ArticleIdList></Reference><Reference><Citation>van Puijenbroek EP, Bate A, Leufkens HG, Lindquist M, Orre R, Egberts AC. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf. (2002) 11:3–10. doi: 10.1002/pds.668</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pds.668</ArticleId><ArticleId IdType="pubmed">11998548</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothman KJ, Lanes S, Sacks ST. The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol Drug Saf. (2004) 13:519–23. doi: 10.1002/pds.1001</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pds.1001</ArticleId><ArticleId IdType="pubmed">15317031</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindquist M, Ståhl M, Bate A, Edwards IR, Meyboom RH. A retrospective evaluation of a data mining approach to aid finding new adverse drug reaction signals in the WHO international database. Drug Saf. (2000) 23:533–42. doi: 10.2165/00002018-200023060-00004</Citation><ArticleIdList><ArticleId IdType="doi">10.2165/00002018-200023060-00004</ArticleId><ArticleId IdType="pubmed">11144660</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou F, Zhu C, Lou S, Cui Z, Wang D, Ou Y, et al. . A real-world pharmacovigilance study of mepolizumab in the FDA adverse event reporting system (FAERS) database. Front Pharmacol. (2023) 14:1320458. doi: 10.3389/fphar.2023.1320458</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2023.1320458</ArticleId><ArticleId IdType="pmc">PMC10771301</ArticleId><ArticleId IdType="pubmed">38186645</ArticleId></ArticleIdList></Reference><Reference><Citation>Sauzet O, Cornelius V. Generalised weibull model-based approaches to detect non-constant hazard to signal adverse drug reactions in longitudinal data. Front Pharmacol. (2022) 13:889088. doi: 10.3389/fphar.2022.889088</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2022.889088</ArticleId><ArticleId IdType="pmc">PMC9445551</ArticleId><ArticleId IdType="pubmed">36081935</ArticleId></ArticleIdList></Reference><Reference><Citation>Sauzet O, Carvajal A, Escudero A, Molokhia M, Cornelius VR. Illustration of the weibull shape parameter signal detection tool using electronic healthcare record data. Drug Saf. (2013) 36:995–1006. doi: 10.1007/s40264-013-0061-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40264-013-0061-7</ArticleId><ArticleId IdType="pubmed">23673816</ArticleId></ArticleIdList></Reference><Reference><Citation>
(FDA) USFaDA . The Abecma Prescribing Information and Medication Guide at DailyMed(2024). Available online at: https://www.accessdata.fda.gov/scripts/cder/rems/index.cfm?event=IndvRemsDetails.page&amp;REMS=406. (accessed [April 15, 2024])</Citation></Reference><Reference><Citation>
(FDA) USFaDA . The Carvykti Prescribing Information at DailyMed 2024. Available online at: https://www.accessdata.fda.gov/scripts/cder/rems/index.cfm?event=IndvRemsDetails.page&amp;REMS=412. (accessed [April 15, 2024])</Citation></Reference><Reference><Citation>Jakubowiak A, Usmani SZ, Berdeja JG, Agha M, Cohen AD, Hari P, et al. . Efficacy and safety of ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma: CARTITUDE-1 subgroup analysis. Blood. (2021) 138:3938–. doi: 10.1182/blood-2021-146069</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2021-146069</ArticleId></ArticleIdList></Reference><Reference><Citation>Raje N, Berdeja J, Lin Y, Siegel D, Jagannath S, Madduri D, et al. . Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N Engl J Med. (2019) 380:1726–37. doi: 10.1056/NEJMoa1817226</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1817226</ArticleId><ArticleId IdType="pmc">PMC8202968</ArticleId><ArticleId IdType="pubmed">31042825</ArticleId></ArticleIdList></Reference><Reference><Citation>Berdeja JG, Madduri D, Usmani SZ, Jakubowiak A, Agha M, Cohen AD, et al. . Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet. (2021) 398:314–24. doi: 10.1016/s0140-6736(21)00933-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(21)00933-8</ArticleId><ArticleId IdType="pubmed">34175021</ArticleId></ArticleIdList></Reference><Reference><Citation>Elsallab M, Ellithi M, Lunning MA, D'Angelo C, Ma J, Perales MA, et al. . Second primary Malignancies after commercial CAR T cell therapy: analysis of FDA adverse events reporting system (FAERS). Blood. (2024) 143(20):2099–105. doi: 10.1182/blood.2024024166</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.2024024166</ArticleId><ArticleId IdType="pubmed">38483155</ArticleId></ArticleIdList></Reference><Reference><Citation>Majzner RG, Mackall CL. Tumor antigen escape from CAR T-cell therapy. Cancer Discovery. (2018) 8:1219–26. doi: 10.1158/2159-8290.Cd-18-0442</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/2159-8290.Cd-18-0442</ArticleId><ArticleId IdType="pubmed">30135176</ArticleId></ArticleIdList></Reference><Reference><Citation>van de Donk N, Usmani SZ, Yong K. CAR T-cell therapy for multiple myeloma: state of the art and prospects. Lancet Haematol. (2021) 8:e446–e61. doi: 10.1016/s2352-3026(21)00057-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s2352-3026(21)00057-0</ArticleId><ArticleId IdType="pubmed">34048683</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L, Shen X, Yu W, Li J, Zhang J, Zhang R, et al. . Comprehensive meta-analysis of anti-BCMA chimeric antigen receptor T-cell therapy in relapsed or refractory multiple myeloma. Ann Med. (2021) 53:1547–59. doi: 10.1080/07853890.2021.1970218</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/07853890.2021.1970218</ArticleId><ArticleId IdType="pmc">PMC8409966</ArticleId><ArticleId IdType="pubmed">34459681</ArticleId></ArticleIdList></Reference><Reference><Citation>Dolladille C, Ederhy S, Ezine E, Choquet S, Nguyen LS, Alexandre J, et al. . Chimeric antigen receptor T-cells safety: A pharmacovigilance and meta-analysis study. Am J Hematol. (2021) 96:1101–11. doi: 10.1002/ajh.26259</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ajh.26259</ArticleId><ArticleId IdType="pubmed">34057232</ArticleId></ArticleIdList></Reference><Reference><Citation>Hazell L, Shakir SA. Under-reporting of adverse drug reactions : a systematic review. Drug Saf. (2006) 29:385–96. doi: 10.2165/00002018-200629050-00003</Citation><ArticleIdList><ArticleId IdType="doi">10.2165/00002018-200629050-00003</ArticleId><ArticleId IdType="pubmed">16689555</ArticleId></ArticleIdList></Reference><Reference><Citation>Alomar M, Tawfiq AM, Hassan N, Palaian S. Post marketing surveillance of suspected adverse drug reactions through spontaneous reporting: current status, challenges and the future. Ther Adv Drug Saf. (2020) 11:2042098620938595. doi: 10.1177/2042098620938595</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2042098620938595</ArticleId><ArticleId IdType="pmc">PMC7418468</ArticleId><ArticleId IdType="pubmed">32843958</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou C, Peng S, Lin A, Jiang A, Peng Y, Gu T, et al. . Psychiatric disorders associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database. EClinicalMedicine. (2023) 59:101967. doi: 10.1016/j.eclinm.2023.101967</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2023.101967</ArticleId><ArticleId IdType="pmc">PMC10149185</ArticleId><ArticleId IdType="pubmed">37131541</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>